Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Lactated Ringer's Solution
Lactated Ringer's · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Indomethacin | DRUG | Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) which is commonly used to reduce inflammation caused by gout, osteoarthritis and rheumatoid arthritis. It acts by blocking the cyclo-oxygenase 1 and 2 (COX) receptors. It has also been implicated to prevent post-ERCP pancreatitis |
| Lactated Ringer's Solution | DRUG | Lactated ringer's solution (LR), is an intravenous fluid (IVF) used commonly during endoscopic procedures and operative procedures. It's composition is similar to that of humans including sodium, chloride, potassium, calcium and lactate. Studies have implicated the use of this fluid in pancreatitis treatment and prevention of post-ERCP pancreatitis |
| Normal Saline | DRUG | standard IVF would include 0.9% normal saline (NS) solution used during all endoscopic procedures. 0.9% NS includes equal parts sodium and chloride. |
| Placebo | DRUG | Placebo would be a suppository 50 mg x 2 |
Lactated Ringer's is an intravenous fluid solution that is being studied for the prevention of post-ERCP acute pancreatitis, a painful inflammation of the pancreas that can occur after an endoscopic procedure of the bile and pancreatic ducts. It is being developed for this gastrointestinal indication by The Cooper Companies, Inc.
Lactated Ringer's is under investigation as a preventive treatment given around the time of an ERCP procedure to reduce the risk of post-ERCP acute pancreatitis. The clinical program has evaluated it both alone and in combination with rectal indomethacin in patients undergoing ERCP.
Lactated Ringer's is being developed by The Cooper Companies, Inc., which trades on the New York Stock Exchange under the ticker COO. The company is pursuing the post-ERCP acute pancreatitis indication through its clinical development program.
Lactated Ringer's is in Phase 3 development for post-ERCP acute pancreatitis. It is an investigational use of the solution and is not approved for this indication. The Phase 3 trial has been completed, and no trials are currently active.
Lactated Ringer's has been studied in one completed Phase 3 trial, NCT02641561, titled Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis. That trial enrolled 192 patients with post-ERCP acute pancreatitis as the condition under study.
Yes, Lactated Ringer's Solution is another name for Lactated Ringer's. Both names refer to the same intravenous fluid being studied for prevention of post-ERCP acute pancreatitis, so searches using either term point to the same development program.